Syncona’s Autolus Gains FDA Approval for Key Leukemia Treatment

Syncona Shs GBP (GB:SYNC) has released an update.

Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL® (obe-cel), a treatment for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant milestone with the U.S. commercial launch underway. This approval triggers a $30 million milestone payment from Blackstone and positions the company for further developments as obe-cel undergoes regulatory review in the EU and UK. Autolus also showcased promising data from ongoing studies and announced key management appointments to advance its innovative therapies.

For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.